Evidence mapPaperPMID 41497351Full record

ReviewDrug design, development and therapy2025

Solidification of SNEDDS Using Mesoporous Carriers (2020-2025): A Review of Design, Biopharmaceutical Enhancement, and Therapeutic Impact.

Sani Ega Priani, Adilah Nurhaliza, Anis Yohana Chaerunisaa, Gofarana Wilar, Iyan Sopyan

Abstract readReview
In one paragraph

Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sani Ega Priani *Doctoral Program of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0001-6544-5463
Adilah Nurhaliza *Department of Pharmacy, Bandung Islamic University, Bandung, Indonesia.ORCID 0009-0007-8808-7348
Anis Yohana Chaerunisaa *Department of Pharmaceutics and Technology of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0002-4985-8206
Gofarana Wilar *Department of Pharmacology and Clinical Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.
Iyan Sopyan *Department of Pharmaceutics and Technology of Pharmacy, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0001-7616-5176

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Self-nanoemulsifying drug delivery systems (SNEDDS) have been widely developed as a practical approach to enhance the bioavailability of poorly water-soluble drugs through nanoscale emulsification. To improve the stability and practicality of liquid systems, solidification is commonly performed to obtain solid SNEDDS (S-SNEDDS) by incorporating appropriate solid carriers. Among various options, mesoporous materials have attracted significant attention due to their high surface area, tunable pore sizes, and excellent adsorption capacity. This review aims to summarize and critically analyze recent advances in mesoporous-based S-SNEDDS, focusing on formulation design, solidification strategies, and associated biopharmaceutical outcomes. The review is based on research articles published between 2020 and 2025 retrieved from reputable scientific databases (PubMed, ScienceDirect, Taylor & Francis, Springer, Scopus, and Web of Science) and selected for their relevance to mesoporous carriers and S-SNEDDS development. Findings reveal that carriers such as mesoporous magnesium alumino-metasilicate (eg, Neusilin

Indexed as

Drug CarriersDrug Delivery SystemsDrug DesignAnimalsBiological AvailabilityEmulsionsHumansPorositySolubilityDrug CarriersEmulsionsadsorption methodbioavailabilitymesoporous carrierssolubility enhancementS-SNEDDS

Identifiers

PMID41497351
PMCPMC12766025

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.